POLB.L Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 18:29):

Stats
Dzisiejszy wolumen	5.01M
Średni wolumen	2.05M
Kapitalizacja rynkowa	66.75M
EPS	£0 ( 2024-04-30 )
Następna data zysków	( £0 ) 2024-05-10
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-13.35
ATR14	£0.0920 (0.69%)

Wolumen Korelacja

Długi: 0.04 (neutral)

Krótki: 0.12 (neutral)

Signal:(43.104) Neutral

Poolbeg Pharma PLC Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Poolbeg Pharma PLC Korelacja - Waluta/Towar

0.07
( neutral )

-0.15
( neutral )

0.00
( neutral )

0.01
( neutral )

0.37
( neutral )

0.09
( neutral )

Poolbeg Pharma PLC Finanse

Annual	2023
Przychody:	£0
Zysk brutto:	£0 (0.00 %)
EPS:	£-0.00790

FY	2023
Przychody:	£0
Zysk brutto:	£0 (0.00 %)
EPS:	£-0.00790

FY	2022
Przychody:	£0
Zysk brutto:	£-26 000.00 (0.00 %)
EPS:	£-0.00940

Financial Reports:

No articles found.

Poolbeg Pharma PLC

Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass intranasally administered RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program. In addition, it is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.